Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

667 Features
Schizophrenia

22 Aug 05

It is often forgotten that until the late 1950s there was no treatment for schizophrenia, or for that matter, any other severe enduring mental illness. The majority of patients admitted to asylum care never left: hence the peak occupancy of 150,000 reported in the UK in 1955. As an interesting comparison, this is twice the current UK prison population.
CSF Medical

Advances in the development of Cav2.2 (N-type) calcium channel blockers as analgesics.

18 Aug 05

According to LeadDiscovery's recent feature report, Pain Therapeutics 2005, about one and a half billion people suffer from moderate to severe chronic pain worldwide, driving the market for analgesics to nearly $23 billion in 2004. Many companies are investing heavily in the development of new pain therapeutics, even more so now with the recent problems to have hit the Cox-II inhibitors. Calcium channel blockers stepped into the spotlight at the end of last year with the FDA approval of Elan's Z
LeadDiscovery

Pancratistatin: A tumor selective apoptosis stimulator

18 Aug 05

Worth an estimated $35 billion in 2003, analysts predict that the sale of oncology therapeutics will grow to $60 billion by 2010. Targeted therapeutics represent one of the most exciting new developments in the field of oncology and include angiogenesis inhibitors; apoptosis stimulators and; signal transduction inhibitors. Apoptosis stimulators lead by Genta's Genesense are particularly appealing. Canadian researchers are focusing on a stimulator of apoptosis known as pancratistatin. This molecu
LeadDiscovery

Simvastatin as a disease modifying immunoregulatory candidate treatment of Parkinson's disease

18 Aug 05

Parkinson's disease drug revenues grew an impressive 17% across the seven major markets to reach $1.7 billion in 2003. Despite the commercial success associated with this therapy area, currently available treatments focus on levodopa which replaces the loss of striatal dopamine, the hall mark of Parkinson's disease, rather than targeting disease progression. The efficacy of levodopa eventually declines in most patients and new therapies with disease modifying activity are urgently required. A gr
LeadDiscovery

The combined use of angiotensin receptor blockers and long-acting calcium channel blockers as an effective approach to hypertension

18 Aug 05

Hypertension continues to represent a highly prevalent clinical problem affecting 190 million people in the 7 major pharmaceutical markets. This therapeutic area is also a highly lucrative field for pharmaceutical companies with sales exceeding $30 billion in 2003. Despite the improved efficacy and tolerability of the angiotensin receptor blocker class led by valsartan, physicians remain frustrated by the lack of efficacy of antihypertensive agents and the current trend is towards the use of com
LeadDiscovery

Histone deacetylase 2 (HDAC2): Modulation of HDAC2 and its implication for chronic obstructive airway diseases (COPD) and cancer.

18 Aug 05

Earlier in 2005, LeadDiscovery published an in depth report on the development of the novel anti-cancer class, the HDAC inhibitors. As this class advances with therapeutic candidates now entering phase II trials, companies are seeking to optimize therapeutic margins by targeting specific isoforms of histone deacetylase that are involved in tumor progression. In a recent NEJM study Prof. Peter Barnes and colleagues demonstrates that the inhibition of HDAC2 could introduce airway risks, possibly e
LeadDiscovery

Dual VEGF- and Erb-receptor inhibition as an improved strategy for treating cancer

18 Aug 05

The overlapping fields of angiogenesis and growth factor biology represent two extensively investigated areas of modern day oncology and the recent success of Avastin, a monoclonal antibody that binds to and neutralizes one such growth factor, VEGF has not only resulted in the introduction of an effective clinical tool for the treatment of cancer but it also helped spark a wave of optimism in the angiogenesis inhibitor arena. As a result companies are evaluating new approaches to target VEGF in
LeadDiscovery

Optimizing gene transfection strategies for the targeted treatment of rheumatoid arthritis

18 Aug 05

Rheumatoid arthritis affects an estimated 2.1 million Americans. The initial success of biologics that neutralize TNF alpha mean that these therapeutics dominate the US and European rheumatoid arthritis markets. Although the development of biologics has revolutionized treatment of rheumatoid arthritis therapies remain far from optimal. Since biologics are peptidic in nature they must be administered by injection. Moreover, multiple dosing is required and this can be disruptive to the patient.
LeadDiscovery

FGF-21 as a candidate for the treatment of diabetes

18 Aug 05

It is estimated that there are more than 38 million people in the seven major markets with diabetes and this figure is set to rise to 50 million in 2012. Despite the presence of well established treatments of diabetes significant unmet needs remain driving a large body of research and development activity. The highlighted JCI paper described work by Lilly researchers advancing FGF-21 or its mimics as a novel therapeutic candidates for the treatment of diabetes.
LeadDiscovery

Actin Inhibition: The identification of PTX-2 as a novel anti-mitotic agent that selectively induces apoptosis in p53 deficient cancer cells

18 Aug 05

Although cytotoxics agents represent a cornerstone of oncology, toxicity and drug resistance has driven the development of targeted anticancer therapies. The current study highlights a novel antimitotic agent, PTX-2. This molecule, like the Taxol and Taxotere, blocks the cell cycle in late mitosis channelling cells into an apoptotic program. In direct contrast to Taxol and Taxotere, PTX-2 targets cells with p53 mutations; the plant alkaloids on the other hand are relatively insensitive in such c
LeadDiscovery

Targeting beta-catenin by celecoxib (Celebrex) as an anti-cancer mechanism of action and as a lead for the identification of improved oncology agents

18 Aug 05

Despite the cardiovascular risks that have recently emerged following prolonged treatment with COX-2 inhibitors, this class of drug continues to receive interest as an approach to chemoprevention. Celebrex, which was approved in 1998 for the treatment of familial adenomatous polyposis (FAP) has been shown to reduce the development of precancerous colorectal polyps by 28%. Data recently highlighted in the FASEB journal suggests that at least part of the efficacy of celebrex may be related to the
LeadDiscovery

Selection and Assessment Day

15 Aug 05

Clinical Research Academy has decided to implement a sure-fire way of finding top candidates for Clinical Research Associate (CRA) posts – by running a Selection and Assessment Day. The first was held at the end of July in Marlow in the UK.
Kieran.Engels

Milestone in the development of Histone Deacetylase Inhibitors

05 Aug 05

This alert is brought to you by LeadDiscovery and concerns today's announcement by Celera Genomics that clinical evaluation of their HDAC inhibitor CRA-024781 is about to commence. The press release is featured on today's edition of DailyUpdates-Oncology.
LeadDiscovery

PharmaReports Alert: Pain Therapeutics 2005

03 Aug 05

This PharmaReports alert (29th June, 2005) from LeadDiscovery announces the most recent report of pain to join the company's porfolio of pain reports. This report, Pain Therapeutics, 2005, provides detailed analysis and information concerning the global market for pain therapeutics, R&D pipelines and company involvement in this field.
LeadDiscovery

A-425619: A TRPV1 receptor antagonist with potential for the treatment of inflammatory, postoperative and arthritic pain

02 Aug 05

The worldwide analgesic market was worth $38 billion during the year 2002 and is expected to nearly double to $75 billion by the year 2010. The vanilloid receptor TRPV1 (VR1) has become an attractive molecular target for multiple sub-types of pain. Abbott researchers have recently described the development of A-425619
LeadDiscovery

Development stage candidate from Bayer Healthcare for the treatment of traumatic head injury, stroke, Parkinson's disease and Alzheimer' s disease

01 Aug 05

Acute neurodegeneration caused by stroke or trauma as well as more chronic disease resulting from Alzheimers’s disease or Parkinson’s disease has inflammatory and direct neurotoxic components. Bayer Healthcare researchers have developed a compound with anti-inflammatory and neuroprotective active resulting is therapeutic activity in models of head injury and Parkinson’s disease
LeadDiscovery

Taishi's 20-HETE synthesis inhibitor, TS-011 as a candidate acute treatment for hemorrhagic and ishemic stroke

28 Jul 05

Each year, 750,000 strokes occur in the US and resultant deaths account for stroke being one of the top three causes of mortality as well as a major economic burden on healthcare systems. One candidate molecular target for stroke is 20-HETE. Taisho Pharmaceutical have developed a potent and selective 20-HETE synthesis inhibitor, TS-011 for the treatment of stroke.
LeadDiscovery

Working in France

28 Jul 05

Tourists love France and why not you… to work and live in France.
Claire Armstrong i3 Pharma Resourcing

Vanilloid receptor desensitization as a strategy for improving glucose tolerance as well as reducing diabetic neuropathic pain

27 Jul 05

The vanilloid capsaicin has long been known to desensitize pain pathways leading to long-term analgesia. Recent data from Novo Nordisk A/S suggests that sensory afferents might also be implicated in the development of glucose intolerance.
LeadDiscovery

So You Want to Contract Staff?

27 Jul 05

It is now the norm for clinical and medical departments to work with a mixture of headcount, freelance and contract employees as well as outsourcing whole projects and there is no indication that going into 2005 and beyond, that there will be any change in this trend.
i3 Pharma Resourcing

Renalase as a new target for the treatment of cardiovascular disease particularly amongst patient with end-stage renal disease

26 Jul 05

The antihypertensive market was valued at $31 billion in 2003. The kidney plays an important role in regulating blood pressure and the renal enzyme renin is a target for what is expected to be the next blockbuster class of anti-hypertensives. The report highlighted here identifies a further renal enzyme, renalase that may be another target for the treatment of hypertension.
LeadDiscovery

Improved assay technology for the evaluation of airway therapeutic activity or toxicology

21 Jul 05

Assaying therapeutic agents requires the availability of apparatus to dose experimental animals as well as to measure biological effect. Available dosing systems for inhalation agents are suboptimal generally causing stress to the animal as well as exposing the operator to potentially harmful agents. Texas based researchers have developed an improved system for the delivery of agents to the airway
LeadDiscovery

Viramidine (Valeant Pharmaceuticals), a ribavirin prodrug for the improved treatment of hepatitis C (HCV) infection

18 Jul 05

Hepatitis C virus (HCV) infection produces cirrhosis, end-stage liver disease and liver cancer and by 2010 38,000 deaths will result from infection. Anemia associated with ribavirin, a common treatment of infected patients represents a major problem. Valeant Pharmaceutical have developed a prodrug of ribavirin, viramidine which is activated within the liver resulting in reduced levels of ribavirin accumulating in red blood cells thus overcoming the problem of anemia.
LeadDiscovery

Novel non-hydroxamic histone deactylase (HDAC) inhibitors in development from Miikana

14 Jul 05

The field of histone deacetylase inhibitors is moving into a new phase of development with candidates advancing nicely through clinical development. Milkana hasve recently developed a series of non-hydroxamic histone deactylase inhibitors which are likely to demonstrate an improved toxcity profile
LeadDiscovery

The mGlu5 receptor: a target for antagonists with improved anxiolytic activity

13 Jul 05

Anxiety disorders affect 20% of the total population across the seven major markets. Recent data demonstrates the efficacy of MPEP, the prototypical mGlu5 receptor antagonist as a an anxiolytic. Efficacy was similar compared to that of diazepam but at anxiolytic doses produces less cognitive decline
LeadDiscovery

DailyUpdates: Breaking Journal Articles & Press Releases for the Drug Development Sector

08 Jul 05

DailyUpdates was developed in 2002 by the drug development consultants, LeadDiscovery. Developed for the R&D community, 1,000's of individuals plus many of the top 20 pharmaceutical companies now use this simple yet effective tool to track key events in the drug discovery sector.
LeadDiscovery

Histone deacetylase inhibitors

06 Jul 05

The field of histone deacetylase inhibitors is moving into a new phase of development. The exponential growth in the level of research activity surrounding the histone deacetylases (HDACs) witnessed over the past decade has now started to produce success in the clinic, particularly in the field of oncology. Over the next few years experts believe that as first generation HDAC inhibitors produce clinical benefits and second generation inhibitors are rationally designed with improved specificity
LeadDiscovery

Aurora Kinase inhibitors

01 Jul 05

Cell cycle inhibitors represent a key approach to the treatment of cancer. Therapeutic agents have traditionally targeted early stages of the cell cycle (ie the G1/S phase checkpoint or the S phase) or mitotic spindle formation as exemplified by the alkaloids. Recently a new approach to cell cycle regulation has emerged with the identification of the Aurora kinase family. This report evaluates this exciting area of drug discovery
LeadDiscovery

TherapeuticAdvance-June 2005

29 Jun 05

Welcome to the June edition of TherapeuticAdvances, LeadDiscovery's free newsletter for the drug development sector. Read on for editorial comment on selected studies recently featured on DailyUpdates our regular bulletin of breaking journal articles and drug development news
LeadDiscovery

Chronic viral hepatitis: B is for billions

28 Jun 05

Despite recent advances in the treatment and management of hepatitis B, the market is still relatively immature, with several key unmet needs. Current pipeline products are expected to account for 89% of total market sales by 2015, however other developmental antivirals are also expected to contribute significantly to future market growth, potentially resulting in new treatment paradigms.
Datamonitor

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.